OJEMDA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OJEMDA (OJEMDA).
OJEMDA is a selective inhibitor of tropomyosin receptor kinases (TrkA, TrkB, TrkC), blocking neurotrophin signaling and inducing apoptosis in TRK fusion-positive tumors.
| Metabolism | OJEMDA is metabolized primarily by CYP3A4 and CYP2C8, with minor contributions from CYP2D6 and CYP2C9. |
| Excretion | Primarily hepatic metabolism; <5% excreted unchanged in urine; biliary/fecal excretion of metabolites accounts for >80% of total clearance. |
| Half-life | Terminal half-life is 12-15 hours in adults; 18-24 hours in pediatric patients; supports once-daily dosing. |
| Protein binding | 99.7% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.6 L/kg, indicating extensive extravascular distribution beyond plasma volume. |
| Bioavailability | Oral bioavailability is 45% (range 30-60%) with high-fat meal increasing AUC by 1.5-fold. |
| Onset of Action | Oral: 1-2 hours to achieve therapeutic plasma concentrations; peak effect on tumor growth inhibition observed within 2 weeks. |
| Duration of Action | 24 hours with once-daily dosing; continuous dosing required for sustained target inhibition; clinical effect duration correlates with trough concentrations above IC90. |
| Molecular Weight | 474.5 |
4 mg orally once daily. Continue until disease progression or unacceptable toxicity.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 2 mg orally once daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment required based on age alone. Monitor for adverse events due to potential age-related comorbidities. |
| 1st trimester | Avoid use in first trimester. Animal studies show teratogenicity and embryolethality at exposures below human therapeutic levels. |
| 2nd trimester | Avoid use in second trimester. Limited human data; potential for fetal harm based on animal data and mechanism of action. |
| 3rd trimester | Avoid use in third trimester. Risk of fetal toxicity and low birth weight; no human pregnancy data. |
Clinical note
Comprehensive clinical and safety monograph for OJEMDA (OJEMDA).
| Placental transfer | Expected to cross placenta based on animal studies and mechanism (kinase inhibitor). Human data not available. |
| Breastfeeding | No data on presence in human milk. Based on molecular weight and high protein binding, excretion into breast milk is unlikely but cannot be excluded. Given the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 week after last dose. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to active substance or any excipientsConcomitant use with strong CYP3A4 inducers
| Precautions | Hepatotoxicity: Elevations of aminotransferases and bilirubin have occurred. Monitor liver function tests before and during treatment., Fetal toxicity: Can cause fetal harm. Advise patients of reproductive potential to use effective contraception., Fertility impairment: May impair fertility in females of reproductive potential., Tumor lysis syndrome: Reported; ensure adequate hydration and monitor electrolytes., Drug-drug interactions: Avoid strong CYP3A4 inducers and inhibitors; adjust dose with moderate CYP3A4 inhibitors. |
| Food/Dietary | Grapefruit and grapefruit juice should be avoided as they may increase OJEMDA plasma concentrations. No other known food interactions. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Fetal risks in first trimester: Based on mechanism of action (EGFR inhibitor), there is potential for teratogenicity; animal studies show embryo-fetal mortality and malformations at clinically relevant exposures. Second and third trimester: Risk of fetal growth restriction, oligohydramnios, and potential for impaired renal function. |
| Fetal Monitoring | Monitor complete blood count, liver function, and serum creatinine monthly; assess blood pressure; fetal ultrasound for growth and amniotic fluid volume every 4 weeks once pregnancy is continued. |
| Fertility Effects | In animal studies, impaired fertility with reduced mating indices and decreased ovarian weights. Human data are lacking; may cause reversible or irreversible impairment of male and female fertility (oligospermia, anovulation). |
| Clinical Pearls | OJEMDA is a selective RET inhibitor for advanced RET fusion-positive non-small cell lung cancer (NSCLC). Monitor for hepatotoxicity, hypertension, and QT prolongation. Dose reduction recommended for moderate hepatic impairment. Avoid use with strong CYP3A4 inhibitors/inducers. Assess renal function prior to initiation. |
| Patient Advice | Take OJEMDA exactly as prescribed, with or without food. · Avoid grapefruit and grapefruit juice during treatment. · Report symptoms of liver injury (yellowing skin/eyes, dark urine, abdominal pain) immediately. · Use effective contraception during therapy and for 2 weeks after the last dose. · Do not breastfeed while taking OJEMDA and for 1 week after the last dose. · Inform your doctor of all medications, including OTC drugs and supplements. |